Related Experiment Video

Updated: Jul 6, 2026

Dual-Dye Optical Mapping of Hearts from RyR2R2474S Knock-In Mice of Catecholaminergic Polymorphic Ventricular Tachycardia
09:36

Dual-Dye Optical Mapping of Hearts from RyR2R2474S Knock-In Mice of Catecholaminergic Polymorphic Ventricular Tachycardia

Published on: December 22, 2023

Ryanodine receptor as a new therapeutic target of heart failure and lethal arrhythmia

Masafumi Yano1

  • 1Department of Medicine and Clinical Science, Division of Cardiology, Yamaguchi University Graduate School of Medicine, 1-1-1 Minamikogushi, Ube 755-8505, Japan. yanoma@yamaguchi-u.ac.jp

Circulation Journal : Official Journal of the Japanese Circulation Society
|March 26, 2008
PubMed

Insights

Abnormal calcium handling in heart failure (HF) involves sarcoplasmic reticulum (SR) dysfunction. Spontaneous calcium release via ryanodine receptor 2 (RyR2) contributes to HF and arrhythmias like CPVT.

Area of Science:

  • Cardiology
  • Molecular Biology
  • Biochemistry

Background:

  • Abnormal intracellular calcium (Ca2+) handling by the sarcoplasmic reticulum (SR) is a key factor in heart failure (HF) development.
  • Dysfunctional Ca2+ uptake and release from the SR impair cardiac contractility and relaxation.
  • Spontaneous Ca2+ release from RyR2 during diastole reduces SR Ca2+ content and causes arrhythmias.

Purpose of the Study:

  • To explore the role of ryanodine receptor 2 (RyR2) in heart failure and cardiac arrhythmias.
  • To investigate the implications of RyR2 mutations in conditions like CPVT and ARVC2.
  • To understand the common abnormalities in RyR2 channel function underlying HF and arrhythmias.

Main Methods:

  • Analysis of sarcoplasmic reticulum Ca2+ handling.
  • Investigation of ryanodine receptor 2 (RyR2) function and mutations.
  • Comparative study of pathological conditions including heart failure, CPVT, and ARVC2.

Main Results:

  • Spontaneous Ca2+ release from RyR2 during diastole is linked to decreased SR Ca2+ content and delayed afterdepolarizations.
  • Disease-linked RyR2 mutations are found in patients with CPVT and ARVC2.
  • Specific mutation patterns suggest regulatory domain interactions within RyR2 are crucial for channel gating.

Conclusions:

  • Common abnormalities in RyR2 channel function contribute to both heart failure and cardiac arrhythmias.
  • Understanding RyR2 dysfunction offers potential for novel therapeutic strategies.
  • Targeting RyR2 may provide new treatments for heart failure and arrhythmias like CPVT and ARVC2.

More Related Videos

Functional Characterization of Endogenously Expressed Human RYR1 Variants07:59

Functional Characterization of Endogenously Expressed Human RYR1 Variants

Published on: June 9, 2021

Related Concept Videos

Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of the heart's...
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...